4//SEC Filing
Kintz Samuel 4
Accession 0001415889-25-008609
CIK 0001672619other
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 5:42 PM ET
Size
5.5 KB
Accession
0001415889-25-008609
Insider Transaction Report
Form 4
Kintz Samuel
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Stock
2025-03-17$20.83/sh−12,500$260,320→ 990,392 total(indirect: See footnote)
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $20.09 to $21.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
Documents
Issuer
Enliven Therapeutics, Inc.
CIK 0001672619
Entity typeother
Related Parties
1- filerCIK 0001967168
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 5:42 PM ET
- Size
- 5.5 KB